Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + bevacizumab + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This regimen is a combination chemotherapy protocol consisting of three drugs: capecitabine (a prodrug of 5-fluorouracil), oxaliplatin (a platinum-based chemotherapeutic), and bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor A). Capecitabine inhibits DNA synthesis by interfering with thymidylate synthase after conversion to 5-FU in the body. Oxaliplatin forms DNA crosslinks, inhibiting DNA replication and transcription. Bevacizumab binds to VEGF-A, preventing angiogenesis required for tumor growth. This combination is primarily used as first-line or second-line therapy for metastatic colorectal cancer (mCRC) and as neoadjuvant therapy for colon cancer[1][2][3][6]. The regimen has demonstrated improved progression-free survival, objective response rates, and disease control rates compared to chemotherapy alone[2][6].
- Brand names
- Xeloda
- Other names
- capecitabine + bevacizumab + oxaliplatinXELOX plus bevacizumab
02
Targets
Beyond the preview
Go deeper on capecitabine + bevacizumab + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + bevacizumab + oxaliplatin.